Brief: Elicera Therapeutics Q1 Adj. EPS at SEK -0.11
16/05/2023 07:22
May 16 (Reuters) - Elicera Therapeutics Q1 adjusted EPS SEK -0.11. * Q1 loss for the period SEK -2.3 million * Q1 operating loss SEK -2.3 million * Q1 cash flow from operating activities SEK -2.04 million
Recent news on Elicera Therapeutics AB
See all newsBrief: Nomination Committee Proposes Margareth Jorvid As Chair Of Elicera Board
Brief: Elicera Therapeutics Carries Out Rights Issue Of About SEK 73 Mln
Sweden's Elicera Therapeutics Q1 loss narrows, reports positive clinical progress
Brief: Elicera Therapeutics Q1 Operating Loss SEK 5.1 Mln
Brief: Elicera Therapeutics Gets Notice Of Allowance For Japanease Patent